NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

U-Act-After: An Observational Study on Long-Term Efficacy of Tight Control RoActemra/Actemra (Tocilizumab) and/or Methotrexate in Patients With Early Rheumatoid Arthritis Who Have Participated in the U-Act-Early Study (ML22497)

NCT01918267

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Rheumatoid Arthritis

Countries: Netherlands

This non-interventional, observational, open-label multi-center follow-up study of patients from the U-Act-Early trial (ML22497) will evaluate the long-term efficacy and safety of starting tight control treatment with RoActemra/Actemra (tocilizumab) and/or methotrexate in patients early in the disease followed by treatment according to standard of care in routine clinical practice in a three year follow-up, independently of what treatment the patient will be receiving.

Eligibility overview

Sex: ALL

Age: 20 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients must have participated in the U-Act-Early trial (ML22497); these are adult patients (\> 20 years of age) with rheumatoid arthritis.
* Patients must be willing to give written informed consent

Exclusion Criteria:

* Patients who did not participate in the U-Act-Early trial
* Patients who are drop-outs in the U-Act-Early trial due to withdrawal of consent, are lost to follow-up or are serious protocol violators

Locations (19)

Alkmaar, Netherlands
Amersfoort, Netherlands
Apeldoorn, Netherlands
Breda, Netherlands
Gorinchem, Netherlands
Gouda, Netherlands
Groningen, Netherlands
Haarlem, Netherlands
Heerlen, Netherlands
Hilversum, Netherlands
Hoofddorp, Netherlands
Leeuwarden, Netherlands
Leiden, Netherlands
Lelystad, Netherlands
Nieuwegein, Netherlands
Nijmegen, Netherlands
Sneek, Netherlands
Utrecht, Netherlands
Woerden, Netherlands